Long Non‑coding RNA MALAT1 Correlates With Cell Viability and Mobility by Targeting miR‑22‑3p in Renal Cell Carcinoma via the PI3K/Akt Pathway

Oncology Reports - Greece
doi 10.3892/or.2018.6853
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

CREB1 Is Affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and Correlates With Adverse Clinicopathological Features in Renal Cell Carcinoma

Scientific Reports
Multidisciplinary
2020English

Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma Through Ezh2 and Interacts With miR-205

Cancer Research
Cancer ResearchOncology
2015English

Long Non-Coding RNA XIST Promotes Cell Growth by Regulating miR-139-5p/PDK1/AKT Axis in Hepatocellular Carcinoma

Tumor Biology
MedicineCancer Research
2017English

FABP5 Regulates the Proliferation of Clear Cell Renal Cell Carcinoma Cells via the PI3K/AKT Signaling Pathway

International Journal of Oncology
Cancer ResearchOncology
2019English

miR-30b-3p Inhibits Proliferation and Invasion of Hepatocellular Carcinoma Cells via Suppressing PI3K/Akt Pathway

Frontiers in Genetics
GeneticsMolecular Medicine
2019English

LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway

Cancer Management and Research
Oncology
2020English

Downregulation of NEAT1 Reverses the Radioactive Iodine Resistance of Papillary Thyroid Carcinoma Cell via miR-101-3p/FN1/PI3K-AKT Signaling Pathway

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2018English

Association of the Long Non-Coding RNA MALAT1 With the Polycomb Repressive Complex Pathway in T and NK Cell Lymphoma

Oncotarget
Oncology
2017English

Long Non‑coding RNA MALAT1 Promotes High Glucose‑induced Rat Cartilage Endplate Cell Apoptosis via the P38/Mapk Signalling Pathway

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy